Camurus withdraws variation application for CAM2038 to include chronic pain
Lund, Sweden — 13 February 2023 — Camurus (NASDAQ STO: CAMX) announced today that it has notified the European Medicines Agency (EMA) of its decision to withdraw the Type II variation application for CAM2038 to include treatment of chronic pain in patients with opioid dependence. The decision is based on Camurus’ assessment of the request from EMA’s Committee for Medicinal Products for Human Use (CHMP) for additional clinical data to support the proposed extended indication for CAM2038 (Buvidal[®]). The pivotal clinical program was aligned with representatives from EMA prior to